查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1993876

医药CDMO市场：按服务类型、技术、治疗方式、最终用途、国家和地区划分－全球产业分析、市场规模、市场份额和预测（2025-2032年）

Pharmaceutical CDMO Market, By Service Type, By Technology, By Therapeutic Modality, By End-Use, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 353 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年，医药 CDMO 市值为 1804.1809 亿美元，预计从 2025 年到 2032 年将以 7.20% 的复合年增长率增长。

合约研发生产机构 (CDMO) 是一家专业服务供应商，致力于帮助製药和生物技术公司开发、生产和销售药品。 CDMO 提供广泛的服务，涵盖製剂开发、製程开发、临床和商业化生产、分析测试以及包装等各个环节。透过与 CDMO 合作，企业可以利用其先进技术、法规专业知识和灵活的生产能力，缩短产品上市时间并提高成本效益。 CDMO 不仅仅是服务供应商，更是策略合作伙伴，尤其是在生物製药和基因疗法等复杂治疗方法，它们能够推动创新、确保品质合规并实现永续成长。各国政府和国际组织，例如美国食品药物管理局 (FDA)、欧洲药品管理局 (EMA) 和世界卫生组织 (WHO)，越来越重视国内生产的韧性和品质标准，并积极推动与 CDMO 的合作，以加强供应链、支持疫苗生产能力并符合全球公共卫生目标。

医药CDMO市场－市场动态

对支持长期医疗保健永续性的先进生物製药的需求日益增长

对先进生物製药日益增长的需求是推动製药生产和外包业务成长的主要动力。这是因为单株抗体、重组蛋白、疫苗和细胞疗法等治疗方法正越来越多地被用于治疗包括癌症、自体免疫疾病和代谢紊乱在内的复杂慢性疾病。製药公司正在拓展其生物製药产品组合以满足这一需求，而主要市场的监管机构也支持这一发展趋势。例如，美国食品药物管理局（FDA）正在积极修订其指导方针，以加速生物相似药和先进生物製药的研发和上市，从而在帮助患者控製成本的同时，提高产品的可及性。

为了满足持续成长的需求，全球领先的製药企业正在扩大产能并投资战略资产。韩国三星生物製剂公司透过收购位于马里兰州的生产设施，增强其生物製药生产能力并扩大在美国的企业发展，以满足长期需求。在政策层面，印度等国已宣布大规模计划以提升其生物製药能力，其中包括一项为期五年、投资1000亿卢比的专项倡议，旨在将印度打造成为全球生物製药和生物类似药生产中心。这些公私合作的协同效应反映了生物製药疗法如何塑造全球永续医疗保健的优先事项。

医药CDMO市场－市场区隔分析：

全球医药CDMO市场按服务类型、技术、治疗方式、最终用途和地区进行细分。

根据服务类型，市场可分为五大类：药物发现支援服务、分析和法规支援、临床生产、商业化生产以及包装和序列化服务。商业化生产在市场中扮演核心角色，因为它能够提供药物完成临床开发阶段后，申办者最迫切需要的大规模生产能力。像龙沙（Lonza）这样的公司就体现了这一领域的重要性。预计到2025年，该公司核心的CDMO业务（专注于小分子和生物製剂平台的商业化生产）销售额将增长至65亿瑞士法郎，占总收入的很大一部分，并推动利润率的提升。政府正在推行的各项倡议，例如美国FDA的「PreCheck」倡议，正透过简化设施审查和加强生产基础设施，优先考虑扩大国内生产规模，这凸显了商业化生产在保障可靠供应和市场进入方面发挥的关键作用。

根据治疗方式，市场可分为五大类：小分子药物、生物製药、先进疗法、疫苗和特殊製剂。小分子药物因其成熟的生产流程和较低的复杂性而仍被广泛应用，而生物製药预计将在合约研发生产机构（CDMO）的需求中占据重要地位，因为它们需要先进的技术、专业的设施和严格的监管合规性。与小分子药物不同，单株抗体、重组蛋白和细胞疗法等生物製药难以在企业内大规模生产。像龙沙（Lonza）和三星生物製剂（Samsung Biologics）这样的公司已在生物製药生产能力方面投入巨资，这反映出它们对外包的高度依赖。包括美国FDA加速生物製药核准计画在内的政府倡议，进一步提升了生物製药作为全球製药生产战略重点的地位。

医药CDMO市场—区域洞察

预计北美将在药品合约研发生产（CDMO）市场中扮演重要角色，主要得益于政府和私营部门持续投资以增强国内药品生产能力。美国食品药物管理局（FDA）已启动多项倡议，例如「预检计画」（PreCheck ）试验计画，旨在简化监管核准，并加速全美各地新建药品生产设施。这些措施与确保基本药物的可靠供应、减少对进口的依赖、加强供应链稳定性以及支持扩大本地生产能力等国家优先事项相一致。

同时，各大製药公司正在扩大在北美的製造地。例如，诺华计划在德克萨斯州新建一座放射性配体疗法製造地，作为其多设施扩建计画的一部分。与此同时，艾伯维正在投资数亿美元，扩大其在伊利诺伊州的原料药（API）生产，这反映出业界对该地区生产能力以及政府奖励充满信心。这些投资不仅将创造就业机会，也显示公共和企业策略规划正在携手合作，将北美打造成为先进製药製造和合约研发生产力（CDMO）活动的中心。

韩国医药CDMO市场—国别分析

凭藉政府的定向支持和蓬勃发展的产业，韩国已成为全球医药CDMO生态系统的重要贡献者。韩国政府已将包括疫苗、mRNA和蛋白质生产技术在内的生物製药列为战略领域，并将其视为加强长期成长和实现自主生产的关键国家优先事项之一。监管机构也考虑推出相关立法，以正式加强CDMO活动和出口生产的框架，这反映了韩国对医药创新和全球供应链的政策重点。

总部位于仁川松岛的三星生物製剂公司，正透过与国际合作伙伴签订大规模生产合约以及持续扩大产能，不断巩固其作为韩国合约研发生产机构（CDMO）的地位。该公司预计到2025年销售额将超过4.5万亿韩元，并已获得多项重要的多年期生产合同，这些合同支撑了对生物製药服务的需求。新增工厂和先进生物製药生产平台的策略性投资，进一步巩固了韩国作为新兴生物製造和合约研发服务中心的地位。

目录

第一章：医药CDMO市场概述

  • 分析范围
  • 市场估算期

第二章执行摘要

  • 市场区隔
  • 竞争考察

第三章：医药CDMO的关键市场趋势

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 未来市场趋势

第四章：医药CDMO产业分析

  • PEST分析
  • 波特五力分析
  • 市场成长前景展望图
  • 管理体制分析

第五章：医药CDMO市场：地缘政治紧张局势加剧的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：医药CDMO市场现状

  • 2024年医药CDMO市占率分析
  • 主要製造商的细分数据
    • 对现有公司的分析
    • 新兴企业分析

第七章 医药CDMO市场：依服务类型划分

  • 概述
    • 细分市场占有率分析：依服务类型划分
    • 药物开发服务
    • 分析和监管支持
    • 临床生产
    • 商业生产
    • 包装和序列化服务

第八章：医药CDMO市场：依技术划分

  • 概述
    • 细分市场占有率分析：依技术划分
    • 化学合成和原料药生产
    • 发酵和生物过程
    • 灌装、精加工和无菌加工
    • 连续製造
    • 先进的分析技术

第九章：医药CDMO市场：依治疗方式划分

  • 概述
    • 细分市场占有率分析：依治疗方式划分
    • 低分子化合物
    • 生物製药
    • 先进的治疗方法（细胞、基因、组织）
    • 疫苗
    • 特殊配方（例如，脂质体、奈米颗粒）

第十章：医药CDMO市场：依最终用途划分

  • 概述
    • 细分市场占有率分析：依最终用途划分
    • 大型製药企业
    • 中型生技公司
    • 虚拟製药
    • 公共卫生计划
    • 非营利研究联盟

第十一章：医药CDMO市场：依地区划分

  • 介绍
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 主要製造商：欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 概述
    • 主要製造商：亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 其他亚太国家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他拉丁美洲国家
  • 中东和非洲
    • 概述
    • 主要生产商：中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他中东和非洲国家

第十二章：主要供应商分析：製药CDMO产业

  • 竞争基准
    • 竞争对手仪錶板
    • 竞争定位
  • 公司简介
    • Catalent
    • Thermo Fisher Scientific
    • Lonza Group
    • Recipharm AB
    • Samsung Biologics
    • WuXi AppTec
    • Cambrex Corporation
    • WuXi Biologics
    • Piramal Pharma Solutions
    • Corden Pharma International
    • Vetter Pharma
    • Eurofins CDMO
    • Others

第十三章：分析师的综合视角

简介目录
Product Code: ANV6159

Pharmaceutical CDMO Market size was valued at US$ 180,418.09 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) is a specialized service provider that supports pharmaceutical and biotechnology companies in developing, producing, and commercializing drugs. CDMOs offer services spanning drug formulation, process development, clinical and commercial manufacturing, analytical testing, and packaging. By partnering with CDMOs, companies gain access to advanced technologies, regulatory expertise, and flexible production capacity, enabling faster time-to-market and cost efficiency. Beyond service provision, CDMOs act as strategic collaborators, particularly for complex therapies such as biologics and gene therapies, fostering innovation, quality compliance, and sustainable growth. Governments and global agencies such as the U.S. FDA, European Medicines Agency, and World Health Organization gradually emphasize domestic manufacturing resilience and quality standards, inspiring CDMO engagement to strengthen supply chains, support vaccine capacity, and align with public health objectives worldwide.

Pharmaceutical CDMO Market- Market Dynamics

Rising demand for advanced biologic therapies to support long-term healthcare sustainability

The rising demand for advanced biologic therapies is a key catalyst for growth in pharmaceutical manufacturing and outsourcing because these therapies, such as monoclonal antibodies, recombinant proteins, vaccines, and cell-based treatments, are increasingly used to treat complex chronic conditions, including cancer, autoimmune diseases, and metabolic disorders. Pharmaceutical companies are expanding their biologics portfolios to meet this need, and regulators in major markets are facilitating this evolution. For instance, the U.S. Food and Drug Administration (FDA) has been actively adapting guidance to accelerate development and access to biosimilars and advanced biologic drugs, helping increase availability while managing costs for patients.

In response to this sustained demand, leading global manufacturers are investing in capacity expansion and strategic assets. South Korea's Samsung Biologics is expanding its presence in the United States by acquiring a Maryland production facility to support biologics output and meet long term demand. On the policy side, countries like India have announced major programmes to bolster biopharmaceutical capabilities, including a dedicated ₹10,000 crore initiative over five years to position the nation as a global hub for biologics and biosimilars manufacturing. These combined public and private commitments reflect how biologic therapies are shaping sustainable healthcare priorities worldwide.

Pharmaceutical CDMO Market- Segmentation Analysis:

The Global Pharmaceutical CDMO Market is segmented on the basis of Service Type, Technology, Therapeutic Modality, End-Use, and Region.

Based on service type market is divided into five categories: Drug Development Services, Analytical and Regulatory Support, Clinical Manufacturing, Commercial Manufacturing, and Packaging & Serialization Services. Commercial Manufacturing act as a central role in the market because it delivers the large scale production capacity that sponsors most urgently need once drugs clear clinical development. Companies like Lonza have shown this segment's importance: in 2025, its core CDMO business - heavily weighted toward commercial manufacturing across small molecule and biologics platforms - grew to CHF 6.5 billion in sales, accounting for a substantial portion of overall revenue and driving expanded margins. Government continuous efforts, such as the U.S. FDA's PreCheck initiative, also reinforce the priority of scaling domestic manufacturing by streamlining facility reviews and enhancing production infrastructure, underscoring commercial manufacturing's pivotal role in supporting reliable supply and market access.

The market is divided into five categories based on therapeutic modality: Small Molecules, Biologic Molecules, Advanced Therapies, Vaccines, and Specialized Formulations. While Small Molecules remain widely used due to established manufacturing processes and lower complexity, Biologic Molecules are expected to play a key role in CDMO demand because they require advanced technologies, specialized facilities, and strict regulatory compliance. Unlike small molecules, biologics such as monoclonal antibodies, recombinant proteins, and cell-based therapies cannot be produced easily at scale in-house. Companies like Lonza and Samsung Biologics invest heavily in biologics manufacturing capacity, reflecting higher outsourcing reliance. Government initiatives, including the U.S. FDA's accelerated biologics approval programs, further reinforce the focus on biologics as a strategic priority in global pharmaceutical manufacturing.

Pharmaceutical CDMO Market- Geographical Insights

North America is expected to play a key role in the Pharmaceutical CDMO market, driven by continued investments from both the government and private sectors to enhance domestic drug production capabilities. The U.S. Food and Drug Administration (FDA) has launched programs such as the PreCheck Pilot Program, which aims to simplify regulatory approvals and expedite the development of new pharmaceutical manufacturing facilities across the United States. These efforts reduce dependence on imports, strengthen supply chain stability, and support the expansion of local manufacturing capacity, in line with national priorities to ensure reliable access to essential medicines.

In parallel, major pharmaceutical companies are increasing their North American manufacturing footprint. For example, Novartis plans to build a new radioligand therapy manufacturing site in Texas as part of a multi-facility expansion, while AbbVie is investing hundreds of millions of dollars to expand API manufacturing in Illinois, reflecting industry confidence in regional capabilities and government incentives for domestic production. These investments not only create employment but also demonstrate how public policy and corporate strategic planning are converging to position North America as a central hub for advanced pharmaceutical manufacturing and CDMO activities.

South Korea Pharmaceutical CDMO Market- Country Insights

South Korea has positioned itself as a significant contributor to the global Pharmaceutical CDMO ecosystem through targeted government support and dynamic industry advancement. The South Korean government has identified biopharmaceuticals as a strategic sector, including technologies for vaccines, mRNA, and protein production, among key national priorities to bolster long term growth and self-reliance. Regulatory authorities are also considering supportive legislation to formally enhance CDMO activities and export manufacturing frameworks, reflecting policy emphasis on pharmaceutical innovation and global supply chains.

At the corporate level, Samsung Biologics, headquartered in Songdo, Incheon, demonstrates South Korea's growing CDMO stature, with substantial manufacturing contracts with international partners and ongoing capacity expansions. The company reported revenues above 4.5 trillion Korean won in 2025 and has secured significant multi-year manufacturing agreements that underline demand for its biopharmaceutical services. Its strategic investments in additional plants and advanced biologics production platforms further reinforce South Korea's role as an emerging hub for biomanufacturing and contract development services.

Pharmaceutical CDMO Market- Competitive Landscape:

The Pharmaceutical CDMO market is highly competitive, comprising global leaders and specialized regional providers offering end-to-end drug development and manufacturing services. Companies compete based on technical expertise, regulatory compliance, manufacturing capacity, quality standards, and time-to-market efficiency. Leading players focus on expanding production facilities, investing in biologics and advanced therapy capabilities, and enhancing analytical and regulatory services. Strategic approaches such as mergers and acquisitions, long-term partnerships with pharmaceutical sponsors, new service launches, and geographic expansion are commonly employed to strengthen market presence. Firms like Lonza, Samsung Biologics, and Catalent exemplify these strategies, reinforcing their global leadership and client reach

Recent Developments:

In January 2026, Zydus completed the establishment of Zylidac Bio LLC, solidifying its U.S. biologics CDMO presence and aligning with regulatory trends supporting secure domestic manufacturing, thereby improving service availability for global biopharmaceutical partners.

In September 2025, Terumo Corporation acquired a drug product plant and quality control operations from WuXi Biologics in Leverkusen, Germany, enhancing its production scale and quality control capabilities for serving both local and international pharmaceutical customers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PHARMACEUTICAL CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Catalent
  • Thermo Fisher Scientific
  • Lonza Group
  • Recipharm AB
  • Samsung Biologics
  • WuXi AppTec
  • Cambrex Corporation
  • WuXi Biologics
  • Piramal Pharma Solutions
  • Corden Pharma International
  • Vetter Pharma
  • Eurofins CDMO
  • Others

GLOBAL PHARMACEUTICAL CDMO MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Drug Development Services
  • Analytical and Regulatory Support
  • Clinical Manufacturing
  • Commercial Manufacturing
  • Packaging & Serialization Services

GLOBAL PHARMACEUTICAL CDMO MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

  • Chemical Synthesis & API Manufacturing
  • Fermentation & Bioprocessing
  • Fill-Finish & Aseptic Processing
  • Continuous Manufacturing
  • Advanced Analytical Technologies

GLOBAL PHARMACEUTICAL CDMO MARKET, BY THERAPEUTIC MODALITY- MARKET ANALYSIS, 2019 - 2032

  • Small Molecules
  • Biologic Molecules
  • Advanced Therapies (Cell, Gene, and Tissue)
  • Vaccines
  • Specialized Formulations (e.g., liposomal, nanoparticle)

GLOBAL PHARMACEUTICAL CDMO MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032

  • Large Pharmaceutical Companies
  • Mid-Size Biotech Firms
  • Virtual Pharma
  • Public Health Programs
  • Non-Profit Research Consortia

GLOBAL PHARMACEUTICAL CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Pharmaceutical CDMO Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Pharmaceutical CDMO Market Snippet by Service Type
    • 2.1.2. Pharmaceutical CDMO Market Snippet by Technology
    • 2.1.3. Pharmaceutical CDMO Market Snippet by Therapeutic Modality
    • 2.1.4. Pharmaceutical CDMO Market Snippet by End-Use
    • 2.1.5. Pharmaceutical CDMO Market Snippet by Country
    • 2.1.6. Pharmaceutical CDMO Market Snippet by Region
  • 2.2. Competitive Insights

3. Pharmaceutical CDMO Key Market Trends

  • 3.1. Pharmaceutical CDMO Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Pharmaceutical CDMO Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Pharmaceutical CDMO Market Opportunities
  • 3.4. Pharmaceutical CDMO Market Future Trends

4. Pharmaceutical CDMO Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Pharmaceutical CDMO Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Pharmaceutical CDMO Market Landscape

  • 6.1. Pharmaceutical CDMO Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Pharmaceutical CDMO Market - By Service Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Service Type, 2024 & 2032 (%)
    • 7.1.2. Drug Development Services
    • 7.1.3. Analytical and Regulatory Support
    • 7.1.4. Clinical Manufacturing
    • 7.1.5. Commercial Manufacturing
    • 7.1.6. Packaging & Serialization Services

8. Pharmaceutical CDMO Market - By Technology

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
    • 8.1.2. Chemical Synthesis & API Manufacturing
    • 8.1.3. Fermentation & Bioprocessing
    • 8.1.4. Fill Finish & Aseptic Processing
    • 8.1.5. Continuous Manufacturing
    • 8.1.6. Advanced Analytical Technologies

9. Pharmaceutical CDMO Market - By Therapeutic Modality

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Therapeutic Modality, 2024 & 2032 (%)
    • 9.1.2. Small Molecules
    • 9.1.3. Biologic Molecules
    • 9.1.4. Advanced Therapies (Cell, Gene, and Tissue)
    • 9.1.5. Vaccines
    • 9.1.6. Specialized Formulations (e.g., liposomal, nanoparticle)

10. Pharmaceutical CDMO Market - By End-Use

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
    • 10.1.2. Large Pharmaceutical Companies
    • 10.1.3. Mid Size Biotech Firms
    • 10.1.4. Virtual Pharma
    • 10.1.5. Public Health Programs
    • 10.1.6. Non Profit Research Consortia

11. Pharmaceutical CDMO Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Pharmaceutical CDMO Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Pharmaceutical CDMO Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Pharmaceutical CDMO Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Pharmaceutical CDMO Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Pharmaceutical CDMO Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Pharmaceutical CDMO Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Catalent
    • 12.2.2. Thermo Fisher Scientific
    • 12.2.3. Lonza Group
    • 12.2.4. Recipharm AB
    • 12.2.5. Samsung Biologics
    • 12.2.6. WuXi AppTec
    • 12.2.7. Cambrex Corporation
    • 12.2.8. WuXi Biologics
    • 12.2.9. Piramal Pharma Solutions
    • 12.2.10. Corden Pharma International
    • 12.2.11. Vetter Pharma
    • 12.2.12. Eurofins CDMO
    • 12.2.13. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us